메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
송인명 (공주대학교) 김동숙 (공주대학교)
저널정보
한국보건의료기술평가학회 보건의료기술평가 보건의료기술평가 제12권 제1호
발행연도
2024.6
수록면
9 - 16 (8page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
As evidence-based software programs to prevent, manage, and treat diseases and disorders, digital therapeutics (DTx) have emerged as a new type of interventions abroad and in Korea. Establishment of regulatory frameworks for DTx has been recognized as a key step to promote use. European countries like Germany and the U.K. apply health technology assessment (HTA) for DTx. Germany is the first country to create the fast-track process and assessment criteria for the reimbursement of prescription DTx by passing the Digitale-Versorgung-Gesetz (translated as Digital Healthcare Act) in 2019. The U.K.’s National Health Service (NHS) first created the evidence standard framework (ESF) for digital technology in 2018 and updated it in 2021. Compliance with the ESF is not a requirement and the framework can be used only as guidelines when NHS evaluates digital health technology to make a purchasing decision. Unlike Germany and the U.K., the U.S. have not yet established a framework for assessment and reimbursement of DTx. In 2023, Korea issued the draft guidelines for the reimbursement of DTx. According to the guidelines, a new DTx is to be listed provisionally for reimbursement from the National Health Insurance for three years. The rationale for the provisional listing is that the manufacturer collects data on the efficacy of DTx, which will later be used for the formal assessment of DTx. This paper will provide a detailed review of the developments in pioneering countries like Germany and the U.K. to inform policies regarding HTA and reimbursement of DTx in Korea.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0